Austerity takes off gloss from Basilea's Toctino forecasts
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceutica reduced its 2011 sales forecast for its hand eczema treatment Toctino (alitretinoin) from around CHF40 million to CHF32-34 million. The company's chief commercial officer, Hans Christian Rohde, said volume growth for the full year for the once-daily retinoid capsule, Basilea's only marketed product, would be around 30%. "It will take longer than anticipated to get to cruising altitude," he said.